PECULIARITIES OF INCIDENCE OF DIGESTIVE HYDROLASES OF THE STOMACH AND PANCREAS IN CHRONIC VIRAL HEPATITIS WITH С
DOI:
https://doi.org/10.61841/cj9c9n80Keywords:
stomach, pancreas, hepatitis, blood hydrolases, pepsinogen, kallikreinAbstract
-- A comprehensive assessment of the state of the pancreas in the group of patients with chronic viral liver lesions revealed a violation of the functional state of the organ in 80% of cases with chronic hepatitis and in 96.3% of cases with cirrhosis [4.6].With combined infection with hepatitis B and C viruses, more pronounced changes in the blood proteinase activity (trypsin and kallikrein activity), a more distinct decrease in antitryptic activity are noted.Exocrine pancreatic function in patients with hepatitis was also more impaired, which was manifested in some studies by a decrease in basal and stimulated secretion, enzyme secretion (especially trypsin and amylase) and bicarbonate production [4,6], in others - by an increase in amylase and lipase activity . Violations of external secretion increase with increasing severity of the main clinical and biochemical syndromes. The content of glucagon and somatostatin in the blood of patients with chronic hepatitis is increased.
Downloads
References
1. Aleinik V.A., Babich S.M., Change in pancreatic secretion with the introduction of various doses of trypsin into the peripheral and portal veins // Journal of Theoretical and Wedge Medical, 2012, No. 5, S.9-12.
2. Babich S. M., Aleinik V. A., Khojimatov G. M. The effect of protease inhibitors on changes in liver utilization of pentagastrin under the influence of trypsin // Therap. Bulletin of Uzbekistan, 2016, No. 3, S.70-74.
3. Kataev S.S. , Vasilieva N.S. and others. Exocrine pancreatic function in patients with chronic hepatitis and cirrhosis of various etiologies. Klin Honey (Moscow). 1993; 71 (6): 37-42.
4. Morozova, TS. The state of the pancreas in patients with chronic diffuse liver diseases of viral etiology and evaluation of the effectiveness of antiviral therapy. Izhevsk, 1997. Abstract of the dissertation of the candidate of medical sciences.
5. Akere A. et al. Upper gastrointestinal endoscopy in patients with cirrhosis: spectrum and prevalence of lesions // Annals of tropical medicine and public health, 2016, V. 9, №2, P. 112.
6. Gregory G.L., La Russo N.F., Miller L.J. Hepatis processing of cholecystokinin peptides. 1. Structural specificity and mechanism of hepatis extraction// Amer.J.Physiol.- 1986.- vol.250, №3.- Pt1, P.344-349.
7. Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, Brouwer KL. Hepatobiliary disposition of the metabolically stable opioid peptide [D-Pen2, D-Pen5]-enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport system// J. Pharmacol. Exp. Ther.,2004,vol.311(3), P.1203-10.
8. Hunter F. M. et al. Serum pepsinogens as markers of response to therapy forHelicobacter pylori gastritis
//Digestive diseases and sciences. – 1993. – V. 38, №. 11. – Р. 2081-2086.
9. Ji B. et al. Human pancreatic acinar cells lack functional responses to cholecystokinin and gastrin
//Gastroenterology. – 2001. – Т. 121. – №. 6. – С. 1380-1390.
10. Katakura Y. et al. Pancreatic involvement in chronic viral hepatitis //World Journal of Gastroenterology: WJG. – 2005. – V. 11. – №. 23. – P. 3508–3513.
11. Konturek J. W. Cholecystokinin in the control of gastric acid and plasma gastrin and somatostatin secretion in healthy subjects and duodenal ulcer patients before and after eradication of Helicobacter pylori
//Journal of physiology and pharmacology: an official journal of the Polish Physiological Society. – 1994. – V. 45. – №. 4 Suppl 1. – Р. 3-66.
12. Lloyd K. C. K. et al. Somatostatin is released in response to cholecystokinin by activation of type A CCK receptors //Peptides. – 1994. – V.15,№. 2. – Р. 223-227.
13. Mazaki-Tovi M. et al. Serum gastrin concentrations in dogs with liver disorders //The Veterinary record, 2012, V. 171, №1, Р. 19-19.
14. Niebergall-Roth E., Singer M. V. Central and peripheral neural control of pancreatic exocrine secretion
//J Physiol Pharmacol. – 2001. – Т. 52. – №. 4 Pt 1. – С. 523-538.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
